Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer

Avoiding phagocytosis-related artifact in myeloid derived suppressor cell T-lymphocyte suppression assays

(2017) Ruth J. Davis et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Dose-dependent enhancement of T-lymphocyte priming and CTL lysis following ionizing radiation in an engineered model of oral cancer

(2017) Megan Morisada et al.   ORAL ONCOLOGY

Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma

(2017) Linda Tran et al.   Cancer Immunology Research

PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation

(2017) Megan Morisada et al.   OncoImmunology

Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells

(2016) E. Beyranvand Nejad et al.   CANCER RESEARCH

SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2

(2016) Danielle F. Eytan et al.   CANCER RESEARCH

Therapeutic Small Molecules Target Inhibitor of Apoptosis Proteins in Cancers with Deregulation of Extrinsic and Intrinsic Cell Death Pathways

(2016) Adeeb Derakhshan et al.   CLINICAL CANCER RESEARCH

Cytotoxic effects of SMAC-mimetic compound LCL161 in head and neck cancer cell lines

(2016) Roman C. Brands et al.   Clinical Oral Investigations

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

(2016) Tanguy Y Seiwert et al.   LANCET ONCOLOGY

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers

(2016) E. C. Moore et al.   Cancer Immunology Research

Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade

(2016) E. Moore et al.   Cancer Immunology Research

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study

(2015) Herbert I. Hurwitz et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Unknown

(2015)   LARYNGOSCOPE

A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma

(2015) R. K. Amaravadi et al.   MOLECULAR CANCER THERAPEUTICS

Comprehensive genomic characterization of head and neck squamous cell carcinomas

(2015)   NATURE

The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNFα-mediated in head and neck squamous cell carcinoma

(2015) Oscar Matzinger et al.   RADIOTHERAPY AND ONCOLOGY

Unknown

(2015)   Oncotarget

Differential response of head and neck cancer cell lines to TRAIL or Smac mimetics is associated with the cellular levels and activity of caspase-8 and caspase-10

(2014) N Raulf et al.   BRITISH JOURNAL OF CANCER

A Surprising Cross-Species Conservation in the Genomic Landscape of Mouse and Human Oral Cancer Identifies a Transcriptional Signature Predicting Metastatic Disease

(2014) M. D. Onken et al.   CLINICAL CANCER RESEARCH

Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors

(2014) Jeffrey R. Infante et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumor Effects of Cisplatin Combined with Tecemotide Immunotherapy in a Human MUC1 Transgenic Lung Cancer Mouse Model

(2014) C.-J. Kao et al.   Cancer Immunology Research

Unknown

(2013)   CA-A CANCER JOURNAL FOR CLINICIANS

CYLD Deubiquitinates RIP1 in the TNFα-Induced Necrosome to Facilitate Kinase Activation and Programmed Necrosis

(2013) David M. Moquin et al.   PLoS One

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†

(2012) M. Reck et al.   ANNALS OF ONCOLOGY

TNF signaling drives myeloid-derived suppressor cell accumulation

(2012) Xueqiang Zhao et al.   JOURNAL OF CLINICAL INVESTIGATION

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

(2012) Thomas J. Lynch et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting IAP proteins for therapeutic intervention in cancer

(2012) Simone Fulda et al.   NATURE REVIEWS DRUG DISCOVERY

New frontiers in promoting tumour cell death: targeting apoptosis, necroptosis and autophagy

(2012) J S Long et al.   ONCOGENE

Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms

(2011) Mikayel Mkrtichyan et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Radiosensitization of Head and Neck Squamous Cell Carcinoma by a SMAC-Mimetic Compound, SM-164, Requires Activation of Caspases

(2011) J. Yang et al.   MOLECULAR CANCER THERAPEUTICS

Catalytic activity of the caspase-8–FLIPL complex inhibits RIPK3-dependent necrosis

(2011) Andrew Oberst et al.   NATURE

It cuts both ways: reconciling the dual roles of caspase 8 in cell death and survival

(2011) Andrew Oberst et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity

(2010) Chrystelle Brignone et al.   Journal of Translational Medicine